-
公开(公告)号：US20250002600A1
公开(公告)日：2025-01-02
申请号：US18696689
申请日：2022-10-05
Applicant: Genmab A/S , BioNTech SE
Inventor： Alexander MUIK , Kristina SCHÖDEL , Nora PENCHEVA , Maria N. JURE-KUNKEL , Ugur SAHIN , Sina FELLERMEIER-KOPF , Patricia GARRIDO CASTRO , Jordan BLUM , Friederike GIESEKE , Esther C. W. BREIJ , Lars GUELEN , Joost NEIJSSEN , Karsten BECKMANN , Claudia PAULMANN , Bart-Jan DE KREUK , Richard G. HIBBERT , Janine SCHUURMAN , Aran LABRIJN , Ivan KUZMANOV
Abstract: The present invention provides combination therapy using a binding agent that binds to human CD137 and to human PD-L1 in combination with a PD-1 inhibitor to reduce or prevent progression of a tumor or treating cancer.
-
2.发明公开公开(公告)号：US20240301078A1
公开(公告)日：2024-09-12
申请号：US18500799
申请日：2023-11-02
Applicant: GENMAB A/S
Inventor： Brian ELLIOTT , Tahamtan AHMADI , Christopher W.L. CHIU , Esther C.W. BREIJ , Ida HIEMSTRA , Maria N. JURE-KUNKEL
IPC: C07K16/28 , A61K31/475 , A61K31/573 , A61K31/675 , A61K31/704 , A61K39/00 , A61K39/395 , A61P35/00 , C07K16/46
CPC classification number: C07K16/2887 , A61K31/475 , A61K31/573 , A61K31/675 , A61K31/704 , A61K39/3955 , A61P35/00 , C07K16/2809 , C07K16/468 , A61K2039/505 , A61K2039/507 , A61K2039/545 , C07K2317/24 , C07K2317/31 , C07K2317/565
Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated, high-risk DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).
-
3.发明申请公开(公告)号：US20220144964A1
公开(公告)日：2022-05-12
申请号：US17559938
申请日：2021-12-22
Applicant: GENMAB A/S
Inventor： Brian ELLIOTT , Tahamtan AHMADI , Christopher W. L. CHIU , Esther C. W. BREIJ , Ida HIEMSTRA , Maria N. JURE-KUNKEL
IPC: C07K16/28 , A61K31/454
Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and lenalidomide.
-
公开(公告)号：US20220112287A1
公开(公告)日：2022-04-14
申请号：US17559935
申请日：2021-12-22
Applicant: GENMAB A/S
Inventor： Brian Elliott , Jenny Jianlin CHEN , Tahamtan AHMADI , Christopher W.L. CHIU , Esther C.W. BREIJ , Ida HIEMSTRA , Maria N. JURE-KUNKEL
IPC: C07K16/28
Abstract: Provided are methods of clinical treatment of chronic lymphoblastic leukemia (CLL) in human subjects using a bispecific antibody which binds to CD3 and CD20.
-
5.发明公开公开(公告)号：US20240034812A1
公开(公告)日：2024-02-01
申请号：US18025203
申请日：2021-09-10
Applicant: GENMAB A/S
Inventor： Brian ELLIOTT , Tahamtan AHMADI , Christopher W.L. CHIU , Esther C.W. BREIJ , Ida HIEMSTRA , Maria N. JURE-KUNKEL
CPC classification number: C07K16/468 , A61P35/00 , C07K2317/565 , C07K2317/31
Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated, high-risk DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).
-
Patent Agency Ranking
公开(公告)号：US20240409653A1
公开(公告)日：2024-12-12
申请号：US18698354
申请日：2022-10-05
Applicant: GENMAB A/S , BIONTECH SE , MSD INTERNATIONAL BUSINESS GMBH
Inventor： Alexander MUIK , Kristina NÜRMBERGER , Nora PENCHEVA , Maria N. JURE-KUNKEL , Ugur SAHIN
Abstract: The present disclosure relates to combination therapy using a binding agent that binds to human PD-L1 and to human CD 13 7 in combination with pembrolizumab to reduce or prevent progression of a tumor or treating cancer.
-
7.发明公开公开(公告)号：US20230312758A1
公开(公告)日：2023-10-05
申请号：US18025204
申请日：2021-09-10
Applicant: GENMAB A/S
Inventor： Brian ELLIOTT , Tahamtan AHMADI , cHRISTOPHER W.L. CHIU , Esther C.W. BREIJ , Ida HIEMSTRA , Maria N. JURE-KUNKEL
CPC classification number: C07K16/468 , A61P35/00 , C07K2317/565 , C07K2317/31
Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and lenalidomide.
-
公开(公告)号：US20240262924A1
公开(公告)日：2024-08-08
申请号：US18570257
申请日：2022-06-20
Applicant: GENMAB A/S , BioNTech SE
Inventor： Ugur SAHIN , Alexander MUIK , Ulf FORSSMANN , Maria N. JURE-KUNKEL , Gaurav BAJAJ , Craig THALHAUSER , Nora PENCHEVA
CPC classification number: C07K16/2878 , A61P35/00 , C07K16/2827 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/31
Abstract: The present invention relates to a method for reducing or preventing progression of a tumor or treating cancer in a subject, comprising administering to the subject a binding agent comprising a first antigen-binding region binding to human CD137, and a second antigen-binding region binding to human PD-L1. The invention further provides a binding agent for use in reducing or preventing progression of a tumor or for use in treatment of cancer.
-
公开(公告)号：US20230312757A1
公开(公告)日：2023-10-05
申请号：US18025202
申请日：2021-09-10
Applicant: GENMAB A/S
Inventor： Brian ELLIOTT , Jenny J. CHEN , Tahamtan AHMADI , Christopher W.L. CHIU , Esther C.W. BRElJ , Ida HIEMSTRA , Maria N. JURE-KUNKEL
CPC classification number: C07K16/468 , A61P35/00 , C07K2317/565 , C07K2317/31
Abstract: Provided are methods of clinical treatment of chromic lymphoblastic leukemia (CLL) inhuman subjects using a bispecific-antibody which binds to CD3 and CD20.
-
10.发明申请公开(公告)号：US20220119544A1
公开(公告)日：2022-04-21
申请号：US17558430
申请日：2021-12-21
Applicant: GENMAB A/S
Inventor： Brian Elliott , Tahamtan AHMADI , Christopher W.L. CHIU , Esther C.W BREIJ , Ida HIEMSTRA , Maria N. JURE-KUNKEL
IPC: C07K16/28 , A61P35/00 , A61K31/675 , A61K39/395 , A61K31/704 , A61K31/475 , A61K31/573
Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated, high-risk DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.053 seconds)
